Fig. 1: The FUTURE trial schema. | Cell Research

Fig. 1: The FUTURE trial schema.

From: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

Fig. 1

*Patients with heavily pretreated mTNBC were stratified into seven arms using FUSCC NGS panel testing and IHC subtyping. NGS next-generation sequencing, IHC immunohistochemistry, mTNBC metastatic triple-negative breast cancer, FUSCC Fudan University Shanghai Cancer Center, LAR luminal androgen receptor, IM immunomodulatory, BLIS basal-like immune-suppressed, MES mesenchymal-like, AR androgen receptor, PD-1 programmed cell death-1, PARPi poly ADP-ribose polymerase inhibitor, VEGF vascular endothelial growth factor, VEGFR vascular endothelial growth factor receptor, mTORi mammalian target of rapamycin inhibitor.

Back to article page